Drugs and patents in ATC class L01EC - B-Raf serine-threonine kinase (BRAF) inhibitors

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ZELBORAF	vemurafenib
TAFINLAR	dabrafenib mesylate
BRAFTOVI	encorafenib
OJEMDA	tovorafenib
>Tradename	>Generic Name

Last updated: July 24, 2026

Market dynamics and patent landscape for ATC Class L01EC BRAF serine-threonine kinase inhibitors

BRAF inhibitors in ATC L01EC form a crowded IP and competitive landscape centered on targeted small molecules, led commercially by dabrafenib and encorafenib plus MEK combinations. Patent portfolios cluster around (1) core kinase inhibition (compound), (2) dosing regimens (including titration and interruption rules), and (3) combination regimens with MEK inhibitors. Loss of exclusivity is product-specific and timing is driven by the latest-lived patents and data exclusivity blocks under the Hatch-Waxman regime.

Commercially, the market has shifted from first-wave single-agent BRAF to BRAF+MEK combinations across melanoma (BRAF V600E/K), with expanding cross-trace use in CRC (BRAF V600E) and pipeline activity that targets resistance biology. IP risk for generics and biosimilar-like substitutes is largely determined by whether the controlling claims remain unexpired at the Orange Book expiration date and whether Paragraph IV filings are already cleared by settlement records.

Which BRAF inhibitors are in ATC class L01EC and how do their markets differ?

ATC L01EC covers small-molecule inhibitors of B-Raf serine-threonine kinase. The major marketed agents tied to BRAF V600 biology include:

Dabrafenib (BRAF inhibitor; melanoma; typically in combination with trametinib)
Encorafenib (BRAF inhibitor; melanoma and CRC; typically in combination with binimetinib)
Vemurafenib and Zelboraf-class historical incumbents (BRAF inhibitor; melanoma; often substituted by more durable BRAF+MEK regimens)

Market structure: why combinations dominate

Clinical practice and payer dynamics favor BRAF+MEK regimens because they improve outcomes and address resistance pathways (MEK inhibition reduces paradoxical pathway reactivation). That creates an IP “stack” where combination-specific regimen patents often outlive core compound protection.

Revenue exposure map (by commercial center of gravity)

Melanoma: highest value concentration for both dabrafenib-based and encorafenib-based franchises.
BRAF V600E metastatic colorectal cancer: materially important for encorafenib+binimetinib where uptake follows biomarker testing penetration and guideline adoption.

What patents protect dabrafenib (BRAF V600) in the US and what claim types matter most?

The dabrafenib patent estate typically bundles claims into:

Core compounds (BRAF inhibitors and analogs)
Pharmaceutical compositions (solid oral dosage form, excipients, particle specifications)
Method-of-treatment (BRAF V600E/K cancers, dosing schedules)
Combination regimens with MEK inhibitors such as trametinib (and sometimes operational dosing rules tied to adverse events)

Patent strategy that extends exclusivity

For BRAF inhibitors, the most durable legal leverage often comes from:

Combination method-of-use claims that specify a sequence, timing, or dose ratio between BRAF and MEK inhibitors
Dosage regimens that reflect clinical management (dose interruption, dose reduction, titration)
Formulation patents aligned to manufacturing scale and bioavailability targets

Litigation leverage points

Patent assertions usually target:

compound manufacture and formulation equivalents for generics
regimen infringement where the generic label or proposed dosing does not match the branded regimen but is alleged to be “equivalent” in use

What patents protect encorafenib (BRAF V600) and how do they structure around MEK combinations?

The encorafenib IP stack is structurally similar but often emphasizes:

Encorafenib core compounds
Encourafenib pharmaceutical compositions
Method-of-treatment claims in BRAF V600E/K tumors
Combination regimen claims with binimetinib including dosing schedules and patient selection language

Combination claims are the exclusivity engine

In encorafenib+binimetinib, many Orange Book listings and patent claims are tied to:

biomarker-defined population (BRAF V600E)
dosing schedule (e.g., once/twice daily cadence rules)
use with binimetinib to block MEK-pathway mediated resistance

Manufacturing/IP barriers

Second-wave entrants face practical barriers when:

the branded regimen depends on specific dosing constraints that new label claims may avoid
formulation and process patents claim non-obvious manufacturing steps that are not addressed by label carve-outs

When do BRAF inhibitors lose exclusivity in the US: compound patents vs Orange Book vs data exclusivity?

US market timing is governed by:

patent term expiration (including PTA adjustments)
FDA data exclusivity (5-year new chemical entity or new clinical investigation and 6-year for pediatric extensions)
regimen/combination patent listings in the Orange Book

How exclusivity timelines typically play out in BRAF franchises

Core compound protection often expires earlier than combination regimen coverage.
Oral formulation patents often add coverage windows around composition claims and bioequivalence method constraints.
Latest-expiring combination method-of-use patents tend to determine generic entry timing.

Generic entry risk windows

Even when an “active ingredient” compound patent expires, generic entry can be delayed if:

combination method claims still block ANDA approval for the branded regimen
Orange Book listings trigger a Paragraph IV challenge that ends in a settlement stay

What is the Orange Book status of dabrafenib and encorafenib combinations (and how does it affect ANDA timing)?

Orange Book status controls ANDA filer incentives by showing:

which patents are listed for approval
the earliest expiration date across listed patents
which patents are subject to Paragraph IV challenges

Filing and launch playbook

Generic entrants often use Paragraph IV to:

force a district court determination for infringement
trigger automatic statutory stay periods if litigation is timely
seek label carve-outs that avoid infringement for specific regimens or populations

Practical outcome: stay vs non-stay

If a generic challenger receives an early favorable ruling or settlement permits:

an at-risk launch before the last-listed patent expires
delayed launch where settlement preserves branded exclusivity

Which companies have filed Paragraph IV challenges for BRAF inhibitors and how many have gone to litigation?

For BRAF inhibitors, Paragraph IV filings typically concentrate on:

dabrafenib
encorafenib
and often on combination tablets/capsules or regimen claims where the ANDA can be drafted to avoid direct regimen infringement.

The most commercially relevant litigation outcomes are those that:

narrow the asserted claim set through claim construction
settle with a carved launch date tied to specific Orange Book patents
result in “design-around” arguments that alter proposed dosing language

A company’s exposure depends on whether the litigation is tied to:

core compound claims (higher risk of exclusion)
combination regimen method claims (risk depends on label design)

What formulation patents for BRAF inhibitors are commonly asserted, and what do they cover?

Formulation patents in oral BRAF inhibitors usually cover:

tablet/capsule composition and excipient selection
dissolution profile targets and bioavailability-improving excipient systems
stability and manufacturing process parameters

Why formulation patents matter to competitors

Competitors cannot rely only on:

matching the API They also must satisfy:
composition constraints
dissolution and absorption equivalence requirements
any manufacturing process claims asserted as infringement theories

Design-around pathways

Typical routes include:

alternative excipient systems
adjusted particle size or solid-state forms
modified process steps that avoid claimed ranges

What method-of-use patents control BRAF inhibitor combination prescribing and how enforceable are they?

Method-of-use claims often specify:

cancer type (melanoma, CRC)
biomarker status (BRAF V600E or V600K)
combination partner (trametinib or binimetinib)
patient population (treatment naïve vs previously treated)
dosing regimens and timing windows

Enforceability dynamics

In practice, enforceability turns on:

whether proposed generic labels include instructions that directly infringe the claim language
whether courts treat label-directed use as induced or direct infringement theories
whether settlement agreements include label design terms that constrain future generic claims

How do dabrafenib+trametinib and encorafenib+binimetinib compare on patent strength and generic risk?

A defensible high-level comparison framework is:

Branded regimen complexity increases generic risk because the label and prescribing instructions must remain consistent with non-infringing use.
Latest-expiring combination method-of-use patents generally create the longest “effective” exclusivity, even after core compound expiration.
Number of Orange Book-listed patents drives the number of potential litigation paths and settlement milestones.

Competitive positioning consequences

If one franchise has fewer latest-lived combination patents, it may face earlier generic entry.
If one franchise has multiple overlapping regimen claims, challengers face more invalidity and non-infringement complexity, increasing settlement probability.

What biosimilar-like risks exist for BRAF inhibitors and why are they low?

BRAF inhibitors are small molecules, not biologics. Biosimilar frameworks do not apply. The relevant risk is generic small-molecule substitution, driven by Hatch-Waxman and Orange Book patent listings, plus manufacturing/process controls for formulations.

What patent litigation affects BRAF inhibitor market access in the US, UK, and EU?

US: Hatch-Waxman-driven litigation

Key litigation themes:

Paragraph IV infringement disputes over compound, composition, and method-of-use claims
induced infringement theories tied to generic labels
settlements that define carved launch dates

UK/EU: parallel patent enforcement

UK and EU proceedings often focus on:

validity challenges for granted patents
scope of protection for combination regimens and dosage regimens
enforcement against local distributors rather than only manufacturers

What settlement agreements and license deals shape launch calendars for BRAF generics?

Market launch timing typically depends on whether:

a settlement grants an agreed entry date and may impose labeling restrictions
a non-settling path results in continued exclusivity through injunctions or post-judgment stays

In BRAF inhibitor cases, settlement agreements often manage:

timing for launch of generics
label content for dosing and patient populations
any ongoing supply obligations during the stay period

How does FDA regulatory status influence patent landscape outcomes for BRAF inhibitors?

FDA status determines both:

which Orange Book patents must be addressed for ANDA approval
how label design interacts with infringement theories

For combination therapy, the labeling often embeds:

dosing schedules
eligibility criteria (biomarker status)
sequencing rules

Those details are frequently central to method-of-use infringement and design-around viability.

What generic entry scenarios exist for BRAF inhibitors and how are they blocked?

Common generic entry scenarios:

ANDA with paragraph IV targeting one or more Orange Book patents
Carve-out label to avoid use instructions that infringe method-of-use claims
At-risk launch contingent on ongoing appellate outcomes

Blockers:

injunctions
settlement stays
inability to draft labels that fully avoid infringement while still supporting therapeutic interchangeability

Key Takeaways

BRAF inhibitor IP is dominated by combination regimen coverage as much as by core compound patents.
US generic entry timing is controlled by the latest-expiring Orange Book-listed patents, particularly method-of-use and dosing regimen claims.
Market competition remains structured around BRAF+MEK regimens, increasing the practical complexity of label design-around strategies.
Litigation and settlements largely determine whether competitors achieve at-risk launch or enter only after agreed stay/expiration milestones.

FAQs

1) What drives the effective exclusivity period for dabrafenib beyond the API patent term?
Combination method-of-use and dosage regimen patents listed in the Orange Book, plus any qualifying exclusivity extensions, typically drive the effective end of exclusivity.

2) Can an ANDA filer avoid infringement for BRAF inhibitor combinations by changing label language?
Only if the proposed label can be drafted to avoid the specific infringement-triggering instructions tied to the asserted method-of-use claims.

3) Which IP categories most often generate Paragraph IV disputes for BRAF inhibitors?
Compound, formulation/composition, and regimen method-of-use patents listed in the Orange Book.

4) Do biosimilar pathways affect competition in BRAF inhibitor markets?
No, because BRAF inhibitors are small molecules; competition is generic-driven under Hatch-Waxman.

5) How do FDA combination labels influence method-of-use patent enforcement?
Label dosing and patient-selection language can create the factual basis for induced infringement theories if it aligns with claimed regimens.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
35 U.S.C. § 271. https://www.law.cornell.edu/uscode/text/35/271
21 U.S.C. § 355(j). https://www.law.cornell.edu/uscode/text/21/355
FDA. Hatch-Waxman information. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda#hatch-waxman

Drugs in ATC Class L01EC

Drugs in ATC Class: L01EC - B-Raf serine-threonine kinase (BRAF) inhibitors